- Home
- ZTEK vs IFRX Comparison
ZTEK vs IFRX Comparison
Compare ZTEK & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZTEK | IFRX |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | Canada | Germany |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 71.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ZTEK | IFRX |
|---|---|---|
| Price | $0.64 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 47.2K | ★ 744.2K |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $657,134.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2225.73 | N/A |
| 52 Week Low | $0.62 | $0.71 |
| 52 Week High | $1.84 | $2.77 |
Technical Indicators
Market Signals| Indicator | ZTEK | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 47.64 |
| Support Level | $0.64 | $0.99 |
| Resistance Level | $0.75 | $1.16 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 50.00 | 56.55 |
Price Performance
Historical ComparisonAbout ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.